Highlights of China International Import Expo (CIIE) 2023 - Amoy Diagnostics Announced Multiple Collaborations with AstraZeneca and Pfizer
AmoyDx announced multiple collaborations with AstraZeneca and Pfizer during the 2023 China International Import Expo (CIIE), held on November 5-10 in Shanghai China. These partnerships aim to jointly promote the development of precision diagnostics
AmoyDx® Microsatellite Instability (MSI) Detection Kit Received NMPA Approval for Pan-Tumor Immunotherapy Companion Diagnostics
National Medical Products Administration (NMPA) granted approval to AmoyDx® Microsatellite Instability (MSI) Detection Kit
Meet us at ESMO 2023
AmoyDx is excited to be part of this incredible gathering for oncology community.
AmoyDx Collaborates with AstraZeneca to Develop a HER2 Companion Diagnostic for Lung Cancer in China
We are thrilled to announce that AmoyDx reaches a new collaboration agreement with AstraZeneca. Under this agreement, the AmoyDx® Essential NGS panel will be used as a companion diagnostic of ENHERTU® to identify HER2 (ERBB2) mutations in patients with no
AmoyDx Signed a Collaboration Agreement with AstraZeneca for HRD Companion Diagnostic
Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company (SZSE: 300685), announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical
Meet our team at 2023 ASCO Annual Meeting in Chicago, June 2-6
Amoydx will be attending the 2023 ASCO Annual meeting held in Chicago, IL from June 2-6.
* Required information
Manage your account info
Change your password